Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
A-Myb CRISPR/Cas9 KO Plasmid (h): sc-404328
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- A-Myb CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the A-Myb genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: A-Myb Antibody (D-12): sc-514682
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
A-Myb CRISPR/Cas9 KO Plasmid (h) | sc-404328 | 20 µg | $397.00 |
Overview
MYBL1 encodes the transcription factor A-Myb, a sequence-specific DNA-binding protein that regulates gene expression programs linked to cell-cycle progression, differentiation, and lineage-restricted proliferation. A-Myb functions within transcriptional networks controlling chromatin-associated processes and checkpoint signaling, influencing the expression of genes involved in DNA replication and mitotic entry. Dysregulated MYBL1 activity or altered regulatory context has been associated with aberrant proliferative states and oncogenic transcriptional programs in multiple tissue settings. As a nuclear transcriptional regulator, A-Myb is frequently studied for its role in coupling developmental cues to coordinated transcriptional outputs.
A-Myb CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MYBL1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MYBL1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MYBL1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish A-Myb protein expression.
This CRISPR knockout system enables efficient generation of MYBL1-deficient cell models for investigation of A-Myb signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MYBL1 exon(s) critical for A-Myb function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MYBL1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by A-Myb CRISPR/Cas9 KO Plasmid (h) and A-Myb CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MYBL1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by A-Myb HDR Plasmid (h) and A-Myb HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MYBL1 homology arms to support homology-directed repair at defined MYBL1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.